Riccardo Dolcetti
Overview
Explore the profile of Riccardo Dolcetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
174
Citations
3575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhatia D, Dolcetti R, Mazzieri R
J Exp Clin Cancer Res
. 2025 Mar;
44(1):98.
PMID: 40089746
In the last two decades, novel and promising cell-based therapies have populated the treatment landscape for haematological tumors. However, commonly exploited T and NK cell-based therapies show limited applicability to...
2.
Raninga P, Zeng B, Moi D, Trethowan E, Saletta F, Venkat P, et al.
Oncogene
. 2025 Mar;
PMID: 40033028
No abstract available.
3.
Khan M, Sedgwick A, Sun Y, Vivian J, Corbett A, Dolcetti R, et al.
Front Immunol
. 2025 Jan;
15:1474652.
PMID: 39877370
Human natural killer (NK) cells can be sub-divided into two functional subsets but the clinical significance of these CD56 and CD56 NK cells in anti-tumour immunity remains largely unexplored. We...
4.
Raninga P, Zeng B, Moi D, Trethowan E, Saletta F, Venkat P, et al.
Oncogene
. 2024 Dec;
PMID: 39706891
The MYC proto-oncogene is upregulated in >60% of triple-negative breast cancers (TNBCs), it can directly promote tumor cell proliferation, and its overexpression negatively regulates anti-tumor immune responses. For all these...
5.
Muraro E, Montico B, Lum B, Colizzi F, Giurato G, Salvati A, et al.
Front Immunol
. 2024 Mar;
15:1336566.
PMID: 38510242
Introduction: About 50% of cutaneous melanoma (CM) patients present activating BRAF mutations that can be effectively targeted by BRAF inhibitors (BRAFi). However, 20% of CM patients exhibit intrinsic drug resistance...
6.
Montico B, Nigro A, Lamberti M, Martorelli D, Mastorci K, Ravo M, et al.
Cytotherapy
. 2023 Dec;
26(2):145-156.
PMID: 38099895
Background Aims: Whole tumor cell lysates (TCLs) obtained from cancer cells previously killed by treatments able to promote immunogenic cell death (ICD) can be efficiently used as a source of...
7.
Pounraj S, Chen S, Ma L, Mazzieri R, Dolcetti R, Rehm B
Cancer Res
. 2023 Dec;
84(3):353-363.
PMID: 38055891
Neoantigen-based cancer vaccines have emerged as a promising immunotherapeutic approach to treat cancer. Nevertheless, the high degree of heterogeneity in tumors poses a significant hurdle for developing a vaccine that...
8.
Lonie J, Brosda S, Bonazzi V, Aoude L, Patel K, Brown I, et al.
Front Immunol
. 2023 Nov;
14:1220129.
PMID: 37965317
A plateau in treatment effect can be seen for the current 'one-size-fits-all' approach to oesophageal adenocarcinoma (OAC) management using neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT). In OAC, the tumour microenvironment...
9.
Zeng B, Moi D, Tolley L, Molotkov N, Frazer I, Perry C, et al.
Cells
. 2023 Aug;
12(16).
PMID: 37626903
Vaccines have been hailed as one of the most remarkable medical advancements in human history, and their potential for treating cancer by generating or expanding anti-tumor T cells has garnered...
10.
Zeng Z, Ngo H, Proctor M, Rizos H, Dolcetti R, Cruz J, et al.
Pigment Cell Melanoma Res
. 2023 Aug;
37(1):45-50.
PMID: 37614154
Treatment of melanomas with targeted and immunotherapies has proven effective, but resistance to both treatments is a common outcome leaving a high proportion of patients without effective alternative treatment options....